Skip to content

DASH Diet, Triglycerides and AIP in Parkinson's Disease

DASH Diet and Cardiometabolic Risk in Parkinson's Disease: Lower Triglycerides and AIP With Higher Adherence

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07402993
Enrollment
70
Registered
2026-02-11
Start date
2024-06-01
Completion date
2024-12-01
Last updated
2026-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Cardiovascular risk, DASH diet, Parkinson's disease

Brief summary

Participants who agreed to participate in the study were informed about the purpose of the research and obtained their consent to participate in the study using an informed consent form. The study was conducted on 70 patients with Parkinson's disease. Participants who volunteered to participate in the study were given a questionnaire form containing sociodemographic characteristics. In addition, participants' anthropometric measurements (body weight, height, waist and hip circumference, Body Mass Index (BMI)), biochemical parameters (fasting blood glucose, HbA1c, triglycerides, LDL cholesterol, triglycerides, total cholesterol, C-reactive protein (CRP), albumin, and hematology markers (hemoglobin (Hb), hematocrit (Htc), leukocytes and platelets, lymphocytes) and serum vitamin D, folic acid, vitamin B12) and nutritional status (food consumption frequency, DASH diet compliance) were obtained. New cardiovascular risk markers such as neutrophil/lymphocyte ratio (NLR), monocyte HDL ratio (MHR), and plasma atherogenic index (PAI) were calculated.

Interventions

OTHERNo intervention (observational study)

No intervention (observational study)

Sponsors

Abant Izzet Baysal University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Individuals over 19 years of age * Individuals who are literate * Individuals diagnosed with Parkinson's Disease

Exclusion criteria

* Individuals who have had an acute infection or inflammatory disease within the past month * Individuals with chronic infectious or inflammatory diseases * Individuals with cancer

Design outcomes

Primary

MeasureTime frameDescription
Questionnaire Form6 monthsSociodemographic characteristics of the individuals (age, constipation status, presence of comorbidities, gender, smoking and alcohol use) were questioned.
Body weight (BW)6 monthsBW was measured using a calibrated digital scale placed on a flat, tiled surface. The scale was sensitive to 100 grams.
Height6 monthsHeight was measured using a stadiometer with the participant's head positioned in the Frankfort plane and feet placed together.
Waist Circumference (WC)6 monthsWC was measured at the midpoint between the lowest rib and the iliac crest (cristal point) using a flexible measuring tape.
Hip Circumference (HC)6 monthsHC was measured at the widest point of the hips using a flexible measuring tape.
Body Mass Index (BMI)6 monthsBMI was calculated by dividing body weight (in kilograms) by the square of height (in meters): BMI = weight (kg) / height² (m²).
Fasting Blood Glucose6 monthsFasting blood glucose was measured using standard laboratory techniques during routine outpatient visits.
Triglycerides6 monthsTriglyceride levels were measured via fasting blood samples analyzed in the outpatient clinic laboratory.
LDL-Cholesterol6 monthsLDL-cholesterol was measured from fasting serum samples using standard enzymatic colorimetric methods.
HDL-Cholesterol6 monthsHDL-cholesterol was measured from fasting serum samples using standard enzymatic colorimetric methods.
C-Reactive Protein (CRP)6 monthsCRP levels were measured using routine laboratory procedures in outpatient visits.
Vitamin D6 monthsSerum vitamin D (25(OH)D) levels were assessed using chemiluminescence immunoassay methods in the outpatient clinic laboratory.
Folic Acid6 monthsSerum folic acid levels were measured using standard automated immunoassay techniques.immunoassay methods in the outpatient clinic laboratory.
Vitamin B126 monthsSerum vitamin B12 concentrations were measured using automated chemiluminescent immunoassay.immunoassay methods in the outpatient clinic laboratory.
Atherogenic Index of Plasma (AIP)6 monthsAIP is a logarithmically transformed ratio of plasma triglycerides to high-density lipoprotein cholesterol \[log₁₀(TG/HDL-C)\], and it is used as a surrogate marker of atherogenicity and cardiovascular risk.
Monocyte-to-High-Density Lipoprotein Cholesterol Ratio6 monthsA biomarker reflecting the balance between inflammatory status (monocytes) and anti-atherogenic lipid components (HDL-C); it has been proposed as an indicator of systemic inflammation and cardiovascular risk.
Total Cholesterol-to-High-Density Lipoprotein Cholesterol Ratio6 monthsA widely used index of atherogenic risk, representing the balance between total cholesterol and protective HDL-C, with higher values indicating increased cardiovascular risk.
Neutrophil-to-Lymphocyte Ratio (NLR)6 monthsA systemic inflammatory marker calculated as the ratio of neutrophils to lymphocytes, commonly used to assess inflammatory status and immune response.
Food consumption frequency6 monthsParticipants were asked about the foods they consumed in the past month from seven groups, including five basic food groups (meat and meat products, milk and dairy products, bread and grains, vegetables and fruits, sugars and fats), beverages, and fast food. Participants were asked how often and in what quantities they consumed these foods using eight options: "every meal," "every day," "5-6 days a week," "3-4 days a week," "1-2 days a week," "once every 15 days," "once a month," and "never." In evaluating food consumption records, responses regarding food consumption frequency were calculated using food consumption frequency. The amounts of food and beverages consumed were multiplied by "3" for "every meal," '1' for "every day," "0.7855" for "5-6 times a week," "0.498" for "3-4 times a week," "0.2145" for "1-2 times a week," "0.067" for "once every 15 days," and "0.033" for "once a month" to obtain the daily average amounts.
Food consumption record6 monthsA single-day food consumption record was obtained using the 24-hour recall method to determine participants' food consumption patterns. The Food and Nutrition Photo Catalog was used to estimate portions to ensure that the amounts of food consumed were assessed accurately and reliably. Based on these records, daily energy and nutrient intakes were calculated using the Nutrition Information System (BEBİS) software, based on the type and amount of food consumed by individuals in the last 24 hours.
DASH diet compliance6 monthsIndividuals' DASH diet compliance scores were calculated based on their food consumption frequency after their energy requirements were calculated. The highest possible score on the DASH diet compliance scale is 8.0. A score of 4.5 or above is considered 'high compliance', while a score below 4.5 is considered 'low compliance'.

Countries

Turkey (Türkiye)

Contacts

PRINCIPAL_INVESTIGATORNurefşan Konyalıgil Öztürk

Abant Izzet Baysal University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026